Lebrikizumab maintains efficacy, safety in patients with atopic dermatitis up to 1 year
Click Here to Manage Email Alerts
Key takeaways:
- Up to 81.7% of lebrikizumab-treated patients maintained responses through week 52.
- Up to 86.8% of patients treated with lebrikizumab plus topical corticosteroids maintained responses through week 40.
Patients taking lebrikizumab for the treatment of moderate to severe atopic dermatitis maintained similar responses regardless of dose frequency, according to results presented at 25th World Congress of Dermatology in Singapore.
“These data are exciting as patients may be able to be controlled long-term using every four-week dosing, regardless of initial dosing or diseases severity," Emma Guttman-Yassky, PhD, the lead investigator of this study and the Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, told Healio. "For some patients even longer periods (once they are fully controlled) may be possible, as seen from the group that has stopped drug and was followed off drug.”
The data were pooled from three studies — ADvocate1, ADvocate2 and ADjoin. The phase 3 ADvocate 1 and 2 trials assessed the induction and maintenance treatment of lebrikizumab monotherapy in patients with moderate to severe AD.
Patients in ADjoin, a long-term extension of five lebrikizumab parent studies, received induction treatment with lebrikizumab plus topical corticosteroids for the treatment of moderate to severe AD.
In the study presented at the congress, researchers evaluated the maintenance of efficacy and safety in patients who had achieved IGA 0 or 1 or EASI 75 after 16 weeks of lebrikizumab treatment once every 2 weeks or once every 4 weeks without use of rescue therapy.
Results showed that most patients maintained both an IGA 0 or 1 and EASI 75 response. Furthermore, the rates were similar between dosage groups.
In ADvocate 1 and 2, 71.2% of patients treated with lebrikizumab once every 2 weeks and 76.9% treated with lebrikizumab once every 4 weeks maintained IGA 0 or 1 through week 52. Similarly, 78.4% and 82.7%, respectively, also maintained EASI 75 at week 52.
Of the patients from ADjoin that were treated with lebrikizumab plus topical corticosteroids once every 2 weeks or once every 4 weeks, 75.4% and 86.8% maintained IGA 0 or 1 and 85.6% and 81.2% maintained EASI 75 by week 40, respectively.
Safety results were also consistent with those previously published, according to the presentation.